Onconova Therapeutics (ONTX) versus The Competition Head to Head Review
Onconova Therapeutics (NASDAQ: ONTX) is one of 45 public companies in the “Biopharmaceuticals” industry, but how does it weigh in compared to its rivals? We will compare Onconova Therapeutics to similar businesses based on the strength of its valuation, profitability, analyst recommendations, institutional ownership, dividends, risk and earnings.
This table compares Onconova Therapeutics and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Onconova Therapeutics Competitors||-12,930.47%||92.90%||-18.58%|
Risk & Volatility
Onconova Therapeutics has a beta of 0.11, indicating that its share price is 89% less volatile than the S&P 500. Comparatively, Onconova Therapeutics’ rivals have a beta of 1.28, indicating that their average share price is 28% more volatile than the S&P 500.
Insider and Institutional Ownership
26.8% of Onconova Therapeutics shares are owned by institutional investors. Comparatively, 45.2% of shares of all “Biopharmaceuticals” companies are owned by institutional investors. 27.3% of Onconova Therapeutics shares are owned by insiders. Comparatively, 14.9% of shares of all “Biopharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
This is a summary of recent ratings and recommmendations for Onconova Therapeutics and its rivals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Onconova Therapeutics Competitors||121||761||1627||59||2.63|
Onconova Therapeutics presently has a consensus target price of $7.33, indicating a potential upside of 199.32%. As a group, “Biopharmaceuticals” companies have a potential upside of 8.96%. Given Onconova Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Onconova Therapeutics is more favorable than its rivals.
Valuation & Earnings
This table compares Onconova Therapeutics and its rivals gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Onconova Therapeutics||$2.36 million||-$22.15 million||-1.04|
|Onconova Therapeutics Competitors||$579.41 million||$241.76 million||-6.54|
Onconova Therapeutics’ rivals have higher revenue and earnings than Onconova Therapeutics. Onconova Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Onconova Therapeutics rivals beat Onconova Therapeutics on 7 of the 12 factors compared.
About Onconova Therapeutics
Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells. It has over three clinical-stage product candidates and various preclinical programs that target kinases, cellular metabolism or cell division in preclinical development. The Company’s lead product candidate, rigosertib, is being tested in both intravenous (IV) and oral formulations as a single agent, and the oral formulation is also being tested in combination with azacitidine, in clinical trials for patients with myelodysplastic syndromes (MDS), and related cancers. Its other product candidates include Briciclib and Recilisib.
Receive News & Ratings for Onconova Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Onconova Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.